Log In
Print
BCIQ
Print
Print this Print this
 

StrataGraft

  Manage Alerts
Collapse Summary General Information
Company Stratatech Corp.
DescriptionSecond-generation cell-based, tissue-engineered human skin substitute developed using NIKS human keratinocytes
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Organ/tissue engineering
Latest Stage of DevelopmentPhase I
Standard IndicationWounds
Indication DetailsPromote healing of the deep partial-thickness component of complex skin defects; Serve as temporary skin replacement in patients with major skin trauma scheduled to undergo autografting; Treat partial and full-thickness skin burns; Treat severe second-degree burns
Regulatory Designation

U.S. - Orphan Drug (Treat partial and full-thickness skin burns)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today